Last 0.54 GBp
Change Today 0.00 / 0.00%
Volume 0.0
AKT On Other Exchanges
Symbol
Exchange
London
Munich
OTC US
As of 3:45 AM 03/28/14 All times are local (Market data is delayed by at least 15 minutes).

ark therapeutics group plc (AKT) Snapshot

Open
0.54 GBp
Previous Close
0.54 GBp
Day High
0.54 GBp
Day Low
0.54 GBp
52 Week High
08/29/13 - 0.80 GBp
52 Week Low
11/6/13 - 0.28 GBp
Market Cap
1.1M
Average Volume 10 Days
0.0
EPS TTM
-0.02 GBp
Shares Outstanding
209.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARK THERAPEUTICS GROUP PLC (AKT)

Related News

No related news articles were found.

ark therapeutics group plc (AKT) Related Businessweek News

No Related Businessweek News Found

ark therapeutics group plc (AKT) Details

Ark Therapeutics Group plc does not have significant operations. Previously, the company was engaged in the provision of contract development and manufacturing services to the pharmaceutical and biotech industry. Ark Therapeutics Group plc was founded in 1997 and is based in London, the United Kingdom.

64 Employees
Last Reported Date: 04/29/13
Founded in 1997

ark therapeutics group plc (AKT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ark therapeutics group plc (AKT) Key Developments

Ark Therapeutics Group plc(LSE:AKT) dropped from FTSE All-Small Index (GBP)

Ark Therapeutics Group plc(LSE:AKT) dropped from FTSE All-Small Index (GBP)

Ark Therapeutics Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2013

Ark Therapeutics Group plc reported unaudited consolidated earnings results for the six months ended June 30, 2013. For the period, the company reported operating profit of £1,396,000 against loss of £6,257,000 a year ago. Profit on ordinary activities before taxation was £1,397,000 against loss of £6,244,000 a year ago. Profit from continuing operations after taxation was £1,397,000 against loss of £6,022,000 a year ago. Profit on ordinary activities after taxation, being retained loss for the period was £1,397,000 or 0.6 pence per diluted share against loss of £6,022,000 or 3.0 pence per diluted share a year ago. Net cash used in operating activities was £1,391,000 against £4,557,000 a year ago.

Ark Therapeutics Group plc Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2012

Ark Therapeutics Group plc announced audited consolidated earnings results for the year ended December 31, 2012. For the year, the company reported revenue from continuing operations recorded totaled £1,818,000, compared to £7,129,000 a year ago. Operating loss was £12,969,000 against £4,452,000 a year ago. Loss on ordinary activities before taxation was £12,963,000 against £4,444,000 a year ago. Loss on ordinary activities after taxation was £12,940,000 against £3,737,000 a year ago. Loss on ordinary activities after taxation, being retained loss for the year were £12,734,000 or 6.2 pence per basic and diluted share against £3,450,000 or 1.8 pence per basic and diluted share a year ago. Total operating loss was £12,763,000 against £4,165,000 a year ago. Net cash used in operating activities was £7,403,000 against £1,647,000 a year ago. Purchase of property, plant and equipment was £108,000 against £97,000 a year ago. Purchase of intangible assets was £40,000 against £204,000 a year ago. Total revenue was £1,865,000 against £7,192,000 a year ago. The principal reason for the increase in the net cash outflow from operating activities for the year was the decrease in license income of £6,500,000. The company’s intangible capital expenditure included license payments to access technology used in Ark's research programmes. The loss from continuing operations before tax increased significantly during the year 2012 compared to 2011. This was as a result of the lower revenue arising from licensing agreements (£6,500,000 in 2011), impairment charges of £3,100,000 and an increase in administration costs associated with fundraising activities, even though restructuring and cost reduction measures were put in place.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKT:LN 0.54 GBp 0.00

AKT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AKT.
View Industry Companies
 

Industry Analysis

AKT

Industry Average

Valuation AKT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.2x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARK THERAPEUTICS GROUP PLC, please visit www.arktherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.